---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-009729"
form_type: "8-K"
ticker: "IRD"
cik: "0001228627"
company_name: "Opus Genetics, Inc."
filed_at: "2025-03-20T23:59:59+00:00"
generated_at: "2026-05-24T09:46:29.123016+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Opus Genetics reports preliminary FY 2024 net loss of $56.8M, cash burn $25.6M

## Summary
- Net loss for FY 2024 expected to be approximately $56.8 million.
- Net cash used in operating activities for FY 2024 approximately $25.6 million.
- Cash and cash equivalents balance as of Dec 31, 2024 approximately $30.3 million.
- All figures are preliminary, unaudited and subject to change upon finalization of audited financials.

## SEC filing metadata
- accession: 0001140361-25-009729
- form_type: 8-K
- ticker: IRD
- cik: 0001228627
- company_name: Opus Genetics, Inc.
- filed_at: 2025-03-20T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1228627/000114036125009729/0001140361-25-009729-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1228627/000114036125009729/ef20045937_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-009729
- JSON: https://secwatch.observer/filing/0001140361-25-009729.json
- Plain text: https://secwatch.observer/filing/0001140361-25-009729.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.